The final, formatted version of the article will be published soon.You have multiple emails registered with Frontiers:Please enter your email address:

这篇文章的最终格式化版本将很快发布。您在Frontiers注册了多封电子邮件：请输入您的电子邮件地址：

If you already have an account, please

如果您已经有账户，请

login

登录名

You don't have a Frontiers account ? You can

你没有Frontiers帐户？你可以

register hereIntroduction: There has been a dramatic global surge in Dengue Fever (DF) in recent years, with projected 100-400 million cases annually and large outbreaks expected every 3-4 years. This concerning scenario is in sharp contrast to the very low availability of Dengue vaccines to meet this spiraling demand, affecting particularly developing countries in Latin American and Africa.

简介：近年来，全球登革热（DF）急剧上升，预计每年有1亿至4亿例病例，预计每3-4年会爆发一次大规模疫情。这种令人担忧的情况与登革热疫苗的供应量极低形成鲜明对比，以满足这种不断上升的需求，尤其影响到拉丁美洲和非洲的发展中国家。

In our study we aim to identify current vaccine development constraints, from a technological perspective, based on clinical trials and patent landscape data. Methods: This study was conducted in a two-step methodology: first, candidates and launched products and methods used in development or as part of Dengue Fever (DF) vaccines have been identified from the Cortellis Drug Discovery Intelligence (CDDI) platform.

在我们的研究中，我们旨在根据临床试验和专利情况数据，从技术角度确定当前疫苗开发的限制因素。方法：本研究采用两步法进行：首先，从Cortellis药物发现智能（CDDI）平台中确定了用于开发或作为登革热（DF）疫苗一部分的候选产品和方法。

Second, the Derwent Innovation database was used to retrieve patent documents related to Dengue vaccines. Data collected in the period 2014-2024 (to identify the candidate and or launched vaccines) and 2018-2022 (to identify patent documents) with claims involving applications to Dengue vaccine development.

。2014-2024年（确定候选疫苗和/或推出的疫苗）和2018-2022年（确定专利文件）收集的数据涉及登革热疫苗开发申请。

We presented these descriptive data in the following format: quantitative and qualitative assessment describing the vaccine development scenario and the claimed vaccine technologies. Results: Our study indicated that 65% of Dengue vaccines are still in Phase 1 of development. The few current dengue vaccines that have reached phase 3 (1) and launched (2) have shown limited levels of individual protection for one or more dengue serotypes and an anemic pipeline of the next generation of more effective tetravalent dengue vaccines.

我们以以下格式提供了这些描述性数据：描述疫苗开发情景和声称的疫苗技术的定量和定性评估。结果：我们的研究表明，65%的登革热疫苗仍处于开发的第一阶段。目前已经达到第3阶段（1）并推出（2）的少数登革热疫苗对一种或多种登革热血清型的个体保护水平有限，并且下一代更有效的四价登革热疫苗的贫血管道。

Although the intelligent use of multiple dengue vaccine formulations in immunizations campaigns can result in an effective protection aga.

尽管在免疫活动中智能使用多种登革热疫苗制剂可以有效保护aga。